Ken Yan Thong1, Mahender Yadagiri2, Dennis Joseph Barnes3, David Stuart Morris4, Tahseen Ahmad Chowdhury5, Ling Ling Chuah6, Anthony Michael Robinson7, Stephen Charles Bain8, Karen Ann Adamson9, Robert Elford John Ryder2. 1. School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. Electronic address: kythong@gmail.com. 2. Department of Diabetes, Endocrinology and Lipid Metabolism, City Hospital, Birmingham, UK. 3. Diabetes/Endocrinology Services, The Tunbridge Wells Hospital, Pembury, UK. 4. Bridgnorth Medical Practice, Northgate Health Centre, Shropshire, UK. 5. Department of Diabetes, The Royal London Hospital, London, UK. 6. Croydon Health Services NHS Trust, Croydon, UK. 7. Department of Endocrinology, Royal United Hospitals, Bath, UK. 8. Abertawe Bro Morgannwg University Board, Swansea, UK. 9. Diabetes Department, St John's Hospital, Livingston, UK.
Abstract
INTRODUCTION: Treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT2) inhibitors may result in genital fungal infections. We investigated possible risk factors for developing such infections among patients treated with the SGLT2 inhibitor dapagliflozin. METHODS: The Association of British Clinical Diabetologists (ABCD) collected data on patients treated with dapagliflozin in routine clinical practice from 59 diabetes centres. We assessed possible associations of patient's age, diabetes duration, body mass index, glycated haemoglobin, renal function, patient sex, ethnicity and prior genital fungal infection, urinary tract infection, urinary incontinence or nocturia, with the occurrence of ≥1 genital fungal infection within 26 weeks of treatment. RESULTS: 1049 out of 1116 patients (476 women, 573 men) were analysed. Baseline characteristics were, mean±SD, age 56.7±10.2years, BMI 35.5±6.9kg/m2 and HbA1c 9.4±1.5%. Only patient sex (13.2% women vs 3.3% men) and prior history of genital fungal infection (21.6% vs 7.3%) were found to be associated with occurrence of genital fungal infections after dapagliflozin treatment, adjusted OR 4.22 [95%CI 2.48,7.19], P<0.001 and adjusted OR 2.41 [95% CI 1.04,5.57], P=0.039, respectively. CONCLUSION: Women and patients with previous genital fungal infections had higher risks of developing genital fungal infections with dapagliflozin treatment.
INTRODUCTION: Treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT2) inhibitors may result in genital fungal infections. We investigated possible risk factors for developing such infections among patients treated with the SGLT2 inhibitor dapagliflozin. METHODS: The Association of British Clinical Diabetologists (ABCD) collected data on patients treated with dapagliflozin in routine clinical practice from 59 diabetes centres. We assessed possible associations of patient's age, diabetes duration, body mass index, glycated haemoglobin, renal function, patient sex, ethnicity and prior genital fungal infection, urinary tract infection, urinary incontinence or nocturia, with the occurrence of ≥1 genital fungal infection within 26 weeks of treatment. RESULTS: 1049 out of 1116 patients (476 women, 573 men) were analysed. Baseline characteristics were, mean±SD, age 56.7±10.2years, BMI 35.5±6.9kg/m2 and HbA1c 9.4±1.5%. Only patient sex (13.2% women vs 3.3% men) and prior history of genital fungal infection (21.6% vs 7.3%) were found to be associated with occurrence of genital fungal infections after dapagliflozin treatment, adjusted OR 4.22 [95%CI 2.48,7.19], P<0.001 and adjusted OR 2.41 [95% CI 1.04,5.57], P=0.039, respectively. CONCLUSION:Women and patients with previous genital fungal infections had higher risks of developing genital fungal infections with dapagliflozin treatment.
Authors: Anastasios Tentolouris; Panayotis Vlachakis; Evangelia Tzeravini; Ioanna Eleftheriadou; Nikolaos Tentolouris Journal: Int J Environ Res Public Health Date: 2019-08-17 Impact factor: 3.390
Authors: Marc Evans; Angharad R Morgan; Zaheer Yousef; Gethin Ellis; Umesh Dashora; Dipesh C Patel; Pam Brown; Wasim Hanif; Johnathan N Townend; Naresh Kanumilli; Jim Moore; John P H Wilding; Stephen C Bain Journal: Drugs Date: 2021-06-23 Impact factor: 9.546